Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE 1
2024-515919-22-00Phase 3Authorised
- Sponsor
- Vir Biotechnology
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of tobevibart and elebsiran in hepatitis D (HDV) (2 arms), sponsored by Vir Biotechnology. Primary endpoints: Composite virologic and biochemical response and Primary safety. Planned start Jun 2025; status: authorised.
02
Drugs
tobevibartelebsiran
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2024-515919-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515919-22-00.